Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-08
2011-03-08
Whiteman, Brian (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07902169
ABSTRACT:
The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention.
REFERENCES:
patent: 4343794 (1982-08-01), Podos et al.
patent: 4617299 (1986-10-01), Knepper
patent: 4652586 (1987-03-01), Nathanson
patent: 4757089 (1988-07-01), Epstein
patent: 4812448 (1989-03-01), Knepper
patent: 5075323 (1991-12-01), Fain et al.
patent: 5242943 (1993-09-01), Louis et al.
patent: 5260059 (1993-11-01), Acott et al.
patent: 5464866 (1995-11-01), Clark et al.
patent: 5545626 (1996-08-01), Stein et al.
patent: 5585401 (1996-12-01), Brandt et al.
patent: 6365576 (2002-04-01), Carr
patent: 6372249 (2002-04-01), Smith et al.
patent: 6489307 (2002-12-01), Phillips et al.
patent: 7176304 (2007-02-01), McSwiggen et al.
patent: 7294504 (2007-11-01), Wang
patent: 7462602 (2008-12-01), Schultz et al.
patent: 7521431 (2009-04-01), Reich et al.
patent: 7579457 (2009-08-01), Khvorova et al.
patent: 7592325 (2009-09-01), Jimenez et al.
patent: 2002/0055536 (2002-05-01), DeWitte et al.
patent: 2002/0114784 (2002-08-01), Li et al.
patent: 2002/0165158 (2002-11-01), King
patent: 2004/0115641 (2004-06-01), Cowsert et al.
patent: 2004/0167090 (2004-08-01), Monahan et al.
patent: 2004/0198640 (2004-10-01), Leake et al.
patent: 2004/0209832 (2004-10-01), McSwiggen et al.
patent: 2004/0224405 (2004-11-01), Leake et al.
patent: 2004/0235031 (2004-11-01), Schultz et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2004/0266707 (2004-12-01), Leake et al.
patent: 2005/0020521 (2005-01-01), Rana
patent: 2005/0171039 (2005-08-01), McSwiggen et al.
patent: 2006/0058266 (2006-03-01), Manoharan et al.
patent: 2006/0094032 (2006-05-01), Fougerolles et al.
patent: 2006/0172963 (2006-08-01), Shepard et al.
patent: 2006/0172965 (2006-08-01), Shepard et al.
patent: 2007/0093435 (2007-04-01), Andrews et al.
patent: 2007/0167384 (2007-07-01), Leake et al.
patent: 1 527 176 (2007-01-01), None
patent: 2406568 (2005-04-01), None
patent: WO 03/057840 (2003-07-01), None
patent: WO 03/070744 (2003-08-01), None
patent: WO 03/087367 (2003-10-01), None
patent: WO 2004/009794 (2004-01-01), None
patent: WO 2004/009796 (2004-01-01), None
patent: WO 2004/029212 (2004-04-01), None
patent: WO 2004/042024 (2004-05-01), None
patent: WO 2005/044976 (2005-05-01), None
patent: WO 2005/045037 (2005-05-01), None
patent: WO 2005/076998 (2005-08-01), None
patent: WO 2005/079815 (2005-09-01), None
patent: WO 2006/083945 (2006-08-01), None
patent: WO 2006/084217 (2006-08-01), None
patent: WO 2006/099353 (2006-09-01), None
Office Action dated Dec. 4, 2009 in corresponding U.S. Appl. No. 11/574,169.
U.S. Appl. No. 11/574,169, filed Jul. 16, 2007, Ana Jimenez et al.
U.S. Appl. No. 11/360,305, filed Feb. 22, 2006, Ana Jimenez et al.
U.S. Appl. No. 12/170,078, filed Jul. 9, 2008, Ana Jimenez et al.
U.S. Appl. No. 12/170,104, filed Jul. 9, 2008, Ana Jimenez et al.
U.S. Appl. No. 12/170,116, filed Jul. 9, 2008, Ana Jimenez et al.
U.S. Appl. No. 12/170,132, filed Jul. 9, 2008, Ana Jimenez et al.
U.S. Appl. No. 12/170,148, filed Jul. 9, 2008, Ana Jimenez et al.
U.S. Appl. No. 12/170,157, filed Jul. 9, 2008, Ana Jimenez et al.
Abrams et al., “Comparison of Three Tonometers for Measuring Intraocular Pressure in Rabbits,” Invest Ophthalmol Vis Sci. Apr. 1996, 37(5):940-944.
Achenbach et al., Oligonucleotide-Based Knockdown Technologies: Antisense Versus RNA Interference,ChemBioChem., 4, pp. 928-935, 2003.
Akashi et al., “Suppression of Gene Expression by RNA Interference in Cultured Plant Cells,” Antisense Nucleic Acid Drug Dev, 2001, 11(6):359-367.
Amaratunga et al., “Inhibition of Kinesin Synthesis and Rapid Anterograde Axonal Transport in Vivo by An Antisense Oligonucleotide,” The Journal of Biological Chemistry, 268(23) pp. 17427-17430, Aug. 15, 1993.
Ambion, “The Basics: RNase Control,” printout from website <<http://web.archive.org/web/20041207234247>>, dated 2004, retrieved on Sep. 17, 2009.
Ambion, Tech Notes 10(4) and siRNA Target Finder (http://www.ambion.com/techlib/misc/siRNA—finder.html, available to the public) retrieved on May 1, 2008, siRNA target hit for SEQ ID No. 139 included.
Banerjee et al., “Control of Developmental Timing by Small Temporal RNAs: a Paradigm for RNA-mediated Regulation of Gene Expression,” Bioessays, 2002, 24(2):119-129.
Banan et al., “The Ins and Outs of RNAi in Mammalian Cells,” Current Pharmaceutical Biotechnology, 5, pp. 441-450, 2004.
Bass, “The Short Answer,” Nature, vol. 411, pp. 428-429, 2001.
Bhattacharya et al., “Cochlin Deposits in the Trabecular Meshwork of the Glaucomatous DBA/2J mouse,” Exp Eye Res., May 2005 80(5):741-744.
Bhattacharya et al., “Proteomics Reveal Cochlin Deposits Associated with Glaucomatous Trabecular Meshwork,” J. Biol. Chem., Feb. 2005b, 18;280(7):6080-6084, Epub Dec. 3, 2004.
Bosher et al., “RNA Interference: Genetic Wand and Genetic Watchdog.” Nat Cell Biol, 2000, 2(2):E31-6.
Braasch et al., “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression,” Biochemistry, 2002, 41(14):4503-4510.
Brummelkamp et al., “A System for Stable Expression of Short Interfering RNAs in Mammalian Cells,” Science, American Association for the Advancement of Science, 2002, 296(5567):550-553.
Busch et al., “Adenylyl Cyclase in Human and Bovine Trabecular Meshwork,” Investigative Ophthalmology & Visual Science, 34(10), pp. 3028-3034, Sep. 1993.
Bunce et al., “Associations between the deletion polymorphism of the angiotensin 1-converting enzyme gene and ocular signs of primary open-angle glaucoma,” Graefes Arch Clin Exp Ophthalmol., Apr. 2005 243(4):294-299. Epub Oct. 13, 2004.
Caplen et al., “Specific inhibition of Gene Expression by Small Double Stranded RNAs in Invertebrate and Vertebrate Systems,” Proc. Natl. Acad. Sci. USA, 2001,98: 9742-9747.
Cho et al., “Small Interfering RNA-Induced TLR3 Activation Inhibits Blood and Lymphatic Vessel Growth,” PNAS, pp. 1-6, Dec. 5, 2008.
Costagliola et al., “Effect of Oral Losartan Potassium Administration on Intraocular Pressure in Normotensive and Glaucomatous Human Subjects,” Exp Eye Res., Aug. 2000, 71(2):167-171.
Costagliola et al., “Effect of Oral Captopril (SQ 14225) on Intraocular Pressure in Man,” Eur. J. Opthalmol, Jan. 1995, 5(1):19-25.
Crooke et al., “Nucleotides in Ocular Secretions: Their Role in Ocular Physiology,” Pharmacology & Therapeutics, 119, pp. 55-73, 2008.
Cullinane et al., “Renin-angiotensin System Expression and Secretory Function in Cultured human Ciliary Cody Nonpigmented Epithelium,” Br J Ophthalmol. Jun. 2002, 86(6):6766-83.
Denkert et al., “Induction of G0/G1 Cell Cycle Arrest in Ovarian Carcinoma Cells by the Ant-Inflammatory Drug NS-398, but not by COX-2-Specific RNA Interference,” Oncogene, 2003, 22:8653-8661.
Diffen, DNA vs. RNA- Difference and Comparison, retrieved from <<http://www.diffen.com/difference/Dna—vs—RNA>> on May 21, 2009.
Diskin et al., “Detection of Differentially Expressed Glycogenes in Trabecular Meshwork of Eyes with Primary Open-Angle Glaucoma,” Investigative Opthalmology & Visual Science, Apr. 2006, 47(4):1491-1499.
Elabashir et al., “Duplexes of 21-Nucleotide RNAs mediate RNA int
de Buitrago Gonzalo González
Gascón Irene
Jiménez Ana I.
Román José P.
Sesto Ángela
Brivanlou Margaret B.
King & Spalding LLP
Sylentis S.A.U.
Whiteman Brian
LandOfFree
Methods and compositions for the treatment of eye disorders... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of eye disorders..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of eye disorders... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2654450